At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on changes announced to the US childhood vaccine schedule.

The contents of the member listings on the BIO Web site may not be reproduced or used in any form without prior written permission from BIO. For more information about members, please refer to the ...

Building on the success of the campaign to date, BIO is announcing a new series produced for us by BBC StoryWorks and launching in 2025. In this new iteration, the series will build on the ...

BIO seeks dynamic, professional candidates with industry expertise and knowledge for our open positions. If you're interested in joining our team, please see the links below to view our current ...

America leads the world in biotechnology innovation, yet the U.S. is the only country where half of every dollar spent on medicine goes to middlemen, hospital markups, and other hidden supply chain ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented ...

Intellectual property is at the center of U.S. biotech leadership. It plays an essential role in the development of lifesaving scientific advances - and the safeguarding of America's national security ...

Is this the first time you’re attending BIO International Convention? This webinar is for you! We’ll cover all the basics of where to go and what to do - plus, you’ll get some insider tips from the ...

“Most favored nation is a deeply flawed proposal that would devastate our nation’s small- and mid-size biotech companies – the very companies that are the leading drivers of medical innovation in the ...

The ORPHAN Cures Act reaffirms Congress’s strong, bipartisan commitment to protect the research and development of new treatments for patients with rare diseases ...

Helpful to have a template to follow and ensure that the information presented is what the agency wants to see.